Brought to you by 
Sarepta options Duke's CRISPR/Cas9 IP for DMD
Nov 2017
Executive Summary
Sarepta Therapeutics Inc. is working with Duke University to develop a treatment for Duchenne muscular dystrophy (DMD) and gains an option to exclusively license the university’s CRISPR/Cas9 gene editing technology in this indication. DMD is a rare muscle-wasting disease caused by a mutation in the dystrophin gene (an essential protein involved in muscular function).
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sarepta options Duke's CRISPR/Cas9 IP for DMD
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice